MedTrace Logo

Comparing Cefepime Versus Cefazolin Plus Ceftazidime for CAPD-associated Peritonitis

NCT02872038 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2017-10-31

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy of empirical antibiotics of CAPD-associated peritonitis with intraperitoneal, continuous dosing of cefepime monotherapy versus combination of cefazolin and ceftazidime. Patients were randomized to be administered either intraperitoneal cefepime 1 g loading then 250 mg all exchanges (treatment group) or cefazolin and ceftazidime (control group) in the same dose.

Conditions

  • Peritoneal Dialysis Associated Peritonitis

Interventions

DRUG

Cefepime

Cefepime intraperitoneal continuous dosing

DRUG

Cefazolin plus Ceftazidime

Sponsors & Collaborators

  • The Kidney Foundation of Thailand

    collaborator UNKNOWN

  • Siam Pharmaceutical Co Ltd

    collaborator UNKNOWN

  • Chulalongkorn University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2016-11-30
Completion
2016-11-30

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02872038 on ClinicalTrials.gov